PBAC's latest decision on Cell-cultured quadrivalent influenza vaccine (surface antigen, inactivated): Recommended with restriction (2024). Considered for Prevention of influenza in children aged 6 months to <5 years, Aboriginal and Torres Strait Islander people aged ≥6 months to <65 years, persons aged ≥6 months to <65 years with medical conditions increasing risk of influenza complications, and pregnant women.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Children aged 6 months to <5 years; Aboriginal and Torres Strait Islander people aged ≥6 months to <65 years; persons aged ≥6 months to <65 years with medical conditions increasing risk of influenza complications; pregnant women.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Immunogenicity (HAI and microneutralisation assays)
Pivotal trial size
1,667 patients
Key trials
V130_10, V130_12
Comparator
QIVe (quadrivalent egg-based influenza vaccine)
Economic model
Not modelled
ICER note
No ICER calculated; this is a vaccine listing submission for which cost-effectiveness was previously assessed at September 2022 meeting. Current submission is for population extension without new economic evaluation.